Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 3, 2010, Pages 161-166

  Kaya, C ^a   Pabuccu, R ^a   Cengiz, S D ^b   Dnder, I ^b  

^a UFUK UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

CRP; Insulin resistance; MDA; PCOS; Statin; Testosterone

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; INSULIN; LUTEINIZING HORMONE; SIMVASTATIN; TARDEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ULTRASOUND;

ADULT; C-REACTIVE PROTEIN; FASTING; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERANDROGENISM; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LUTEINIZING HORMONE; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; PYRROLES; SIMVASTATIN; TESTOSTERONE; YOUNG ADULT;

EID: 77949536645     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1220770     Document Type: Article

References (36)

1. Ashwell M, Chinn S, Stalley S, Garrow JS. Female fat distribution-a simple classification based on two circumference measurements. Int J Obes 1982 6 143-152
2. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003 9 505-514
3. Belli SH, Graffigna MN, Oneta A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004 81 624-629
4. Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 2007 49 1442-1447
5. Banaszewska BL, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007 92 456-461
6. Boulman N, levy Y, Leiba R, Schachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004 89 2160-2165
7. Dale PO, Tanbo T, Vaaler S, etal. Body weight, hyperinsulinemia, and gonadotrophin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 1992 58 487-491
8. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, etal. A survey of the polycystic ovary syndrome in the Greek Island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999 84 4006-4011
9. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Endocrinol and Metabol 2007 18 281-285
10. Duleba AJ, Foyouzi N, Karaca H, Pehlivena T, Kwintkiewicz J, Behrman HR. Proliferation of ovarian theca-interstitial cells is modulated by antioxidants and oxidative stres. Hum reprod 2004 19 1519-1524
11. Duleba AJ, Banaszewska B, Spacynski RZ, Pawelcyzyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 2006 85 996-1001
12. Expert Committee on the Diagnosis and Classification. Follow-up Report on the Diagnosis of Diabetes Mellitus Diabetes Care. 2003 26 3160-3167
13. Ferriman D, Gallway JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961 21 1440-1447
14. Gl F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmakother 2004 58 614-618
15. Huptas S, Geiss HC, Otto C, Parhofer G. Effect of Atorvastatin (10mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006 98 66-69
16. Izquierdo D, Foyoyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 2004 82 (Suppl 3) 1193-1197
17. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels. Circulation 2001 103 1933-1935
18. Kaya C, Cengiz SD, Berker B, Demirta S, Cesur M, Erdoan G. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2008 Aug 8 [Epub ahead of print]
19. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001 86 2453-2455
20. Kwintkiewicz J, Foyouzi N, Piotrowski P, Rzepczynska I, Duleba AJ. Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen-activated protein kinase patway. Fertil steril 2006 86 (Supp 3) 1053-1058
21. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001 86 713-718
22. Shaw LJ, Bairey MNC, Aziz R, Stanczyk FZ, Sopko G, Braunstein GD, etal. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the national institutes of healthnational heart, lung, and blood institute sponsored women's ischemia syndrome evaluation. J Clin Endocrinol Metab 2008 93 1276-1284
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Tracher DF, Turner RI. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419
24. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: lipid production and beyond. J Clin Endocrinol Metab 2002 887 1451-1458
25. Nelson VL, Legro RS, Staruss JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999 13 946-957
26. Okon MA, Laird SM, Tuckerman EM, Li TCS. Androgens levels in women who have recurrent miscarriage and their correlation with markers of endometrial function. Fertil Steril 1998 69 (4) 682-690
27. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000 102 2165-2168
28. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, etal. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation 2003 107 499-511
29. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 82 (Suppl 3) 1193-1197
30. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochemistry 2001 34 407
31. Sakara M, Tasaka K, Kurachi H, etal. Changes of bioactive luteinising hormone after laparoscopic ovarian cautery in patients with polycystic ovarian syndrome. Fertil Steril 1990 53 611-613
32. Sing U, Devaraj S, Jialal I, Siegel D. Effect of Atorvastatin (10 versus 80mg) on Biomarkers of Inflammation and Oxidative Stress in Subjects With Metabolic Syndrome. Am J Cardiol 2008 102 321-325
33. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of Inflammation in atherosclerosis. J Nucl Med 2007 48 1800-1815
34. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, etal. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995 95 15 821-826
35. Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidegenesis by adrenals and gonads. J Clin Endocrinol Metab 1995 80 836-840
36. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, etal. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002 106 913-919